نتائج البحث - Garry Schwartz

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study حسب Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies

    Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies حسب Quincy Chu, Garry Schwartz, Johann S. de Bono, Deborah A. Smith, Kevin M. Koch, M. Versola, Lini Pandite, Nikita Arya, J. Curtright, Ronald A. Fleming, Peter Ho, Eric K. Rowinsky

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial

    Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial حسب Mark A. Socinski, Thomas E. Stinchcombe, Dominic T. Moore, Scott Gettinger, Roy H. Decker, W. Jeffrey Petty, A. William Blackstock, Garry Schwartz, Scott P. Lankford, Amir H. Khandani, David E. Morris

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

    Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules حسب Anthony W. Tolcher, Stanton L. Gerson, Denis Lairon, Christiane Geyer, L. A. Hammond, Amita Patnaik, Andrew Goetz, Garry Schwartz, Tammy L. Edwards, Larisa Reyderman, Paul Statkevich, David L. Cutler, Eric K. Rowinsky

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer

    Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer حسب Eric K. Rowinsky, Garry Schwartz, Jared Gollob, John A. Thompson, Nicholas J. Vogelzang, Robert A. Figlin, Ronald M. Bukowski, Naomi B. Haas, Pamela Lockbaum, Yu-Ping Li, Rosalin Arends, Kenneth A. Foon, Gisela Schwab, Janice Dutcher

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

    Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody حسب Kenneth A. Foon, Xiao-Dong Yang, Louis M. Weiner, Arie S. Belldegrun, Robert A. Figlin, Jeffrey Crawford, Eric K. Rowinsky, Janice P. Dutcher, Nicholas J. Vogelzang, Jared Gollub, John A. Thompson, Garry Schwartz, Ronald M. Bukowski, Lorin Roskos, Gisela Schwab

    منشور في 2004
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    <i>In vivo</i> assessment of the metabolic activity of CYP2D6 diplotypes and alleles

    <i>In vivo</i> assessment of the metabolic activity of CYP2D6 diplotypes and alleles حسب Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven M. Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R. Carrizosa, Steven Corso, Garry Schwartz, Jeffrey Peppercorn, James P. Evans, D. I. Jones, Zeruesenay Desta, David A. Flockhart, Lisa A. Carey, William Irvin

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity

    Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity حسب Daniel L. Hertz, Allison M. Deal, Joseph G. Ibrahim, Christine M. Walko, Karen E. Weck, Steven M. Anderson, Gustav Magrinat, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R. Carrizosa, Steven Corso, Garry Schwartz, Mark L. Graham, Jeffrey Peppercorn, David Jones, Zeruesenay Desta, David A. Flockhart, James P. Evans, Howard L. McLeod, Lisa A. Carey, William Irvin

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: